Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring

Model scores of the 29,894 trials active now.

Model score 3% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (233 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-07-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: or equaladequatestatusmyocardialinfarction
  Phrases that lowered it: healthyeffect ofthe pharmacokineticsopen labelthe effect
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Drug's FAERS reports marked serious: 34.5% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Sponsor's past termination rate: 6.0% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 1.1% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 130 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past trials: 583 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 113178 (lowers risk) · Drug's FDA history
• Number of arms: 4 (lowers risk) · Design
• Blinding: none (lowers risk) · Design
• Primary purpose: diagnostic (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 50 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days NCT03363997 · started 2016 · scored riskier than 2% of active trials completed
• A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women NCT02092571 · started 2014 · scored riskier than 2% of active trials completed
• A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components NCT03562624 · started 2018 · scored riskier than 4% of active trials completed
• Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women NCT02403401 · started 2015 · scored riskier than 6% of active trials completed
• Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone NCT01597986 · started 2012 · scored riskier than 2% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.